Inebilizumab Calms Flares in IgG4-RD With Pancreas or Hepatobiliary Involvement

Meeting Coverage
>
EASL

—
Drug reduced flare risk by 97% in the pancreas; no flares experienced in hepatobiliary groups

by
Mike Bassett, Staff Writer, MedPage Today
May 10, 2025 • 3 min read

Last Updated
May 16, 2025 • 3 min read

Inebilizumab (Uplizna) treatment significantly reduced the risk of flares in patients who had IgG4-related disease (IgG4-RD) with involvement in the pancreas, bile ducts, or liver, according to a post-hoc analysis of the MITIGATE trial.

Of the 42 patients with pancreas or hepatobiliary involvement who were treated with inebilizumab, just one experienced a disease flare, compared with 32 of 42 patients who experienced a flare while on placebo, reported Emma L. Culver, MD, PhD, of the University of Oxford in England.

When broken further down by organ involvement, one of 27 patients with pancreas involvement had a flare with inebilizumab versus 17 of 24 on placebo (HR 0.13, 95% CI 0.00-0.21, P